Sandoz 2026 Sales Rise 5% at CC as Biosimilars Climb 19%; Core-EBITDA Margin Guidance Upgraded to 23.0-23.5%
Sandoz 2026 sales reached USD 8,703 million in the first nine months, up 5% at constant currencies, with biosimilars up 19% and generics down 1%. The company narrowed full-year net-sales growth guidance to 5-6% and upgraded its core-EBITDA margin outlook to 23.0-23.5%.
